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ABSTRACT 
 
Alzheimer’s disease is a most common amyloid-associated disorder, irreversible, 
progressive brain disorders that leads to change in nerve cells destroying the thinking, 
memory, remembering, reasoning and skills of individuals. The symptom of Alzheimer’s, 
disease generally appears in the individuals having age more than 65 years. The 
neuropathological hallmarks of AD include presence of senile plaques (NP) and 
neurofibrillary tangles (NFT). Amyloid Beta precursor protein cleaving enzyme (BACE-1) or 
Memapsin-2 is a single-membrane protein belongs to the Aspartyl protease family, 
responsible for the processing of the amyloid Precursor protein (APP). The cleavage of APP 
by BACE-1 leads to production of two peptide fragments Amyloid beta peptide (A) 40 and 
42. A42 is thought to be responsible for the neurotoxicity and amyloid plaque formation in 
Alzheimer’s disease (AD). Thus BACE-1 will be an important drug target for the generation 
of inhibitors that lower Aβ. We aim to identify potential natural product inhibitors of beta 
secretase which can be further developed as drug to treat Alzheimer’s disease. Here, we have 
performed in silico virtual screening approach of a natural product database consists of 800 
different chemical molecules. Beta secretase (PDB ID: 1FKN) was used in screening process, 
and docking studies to identify potential lead compounds. The  sorting of compound were 
done based upon their binding energy and top 50 ranked protein- inhibitor complexes were 
selected. We have reported some compound like Spermine, Netilmicinsulfate, and 
Spermidine Trihydrochloride molecule which could be potential inhibitors of beta secretase. 
The ligplot image also provided some idea about the inhibitors that they can attain at the 
active site of beta secretase.  
Keywords; BACE-1; Beta secretase; Memapsin; Alzheimer; Amyloid; Aspartyl protease. 
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1. INTRODUCTION 
 
Alzheimer’s disease is a most common amyloid-associated disorder, unalterable, 
progressive brain disorders that leads to change in nerve cells destroying the thinking, 
memory, remembering, reasoning and skills of individuals[1]. Alzheimer’s disease patient 
have Insoluble, extracellular amyloid plaques, consist of fibrillar aggregates of the amyloid-
beta (Aβ) peptide, a product of the proteolytic cleavage of β-amyloid precursor protein 
(APP)[2].Two enzymes, γ- secretase and β-secretase (BACE-1 or Memapsin-2), are 
responsible for the sequential cleavage of APP for the production of Aβ peptide.  
 
Alzheimer’s disease is a chronic and progressive neurodegenerative disorder causing 
dementia in the individuals having age more than 65. The numbers of Alzheimer’s disease 
patients in united states of America are ranging from 3–5 million having an annual estimated 
cost of approximately $95 billion. The Alzheimer’s disease pathological hallmarks consist of 
presence of extracellular senile plaques and intracellular neurofibrillary tangles 
(NFT).Because neurofibrillary tangles are intracellular fibrillar aggregates of the 
microtubule-associated protein tau that exhibit oxidative modifications and 
hyperphosphorylation[3]. Extracellular senile Plaques and neurofibrillary tangles are present 
in the regions of brain that involved hippocampus, entorhinal cortex, and basal forebrain. Aβ 
damages synapses and neurites by interacting with plaques and tangles. Due to which 
glutamate or acetylcholine neurotransmitters producer neurons are affected mostly, but 
serotonin and nor-epinephrine neurotransmitters producing neurons damaged.  
 
Generally APP was rapidly cleaved and secreted at high levels and the cleavage done 
by α- secretase produce residues K16 and L17 of Aβ and generated a secreted derivative, 
sAPPα, and a membrane bound 83 residue fragment CTFα. The pathway that leading to Aβ 
3 
 
includes the presence of sAPPβ and CTFβ is a membrane bound 99-residue length fragment. 
The processing of CTFβ and CTFα by γ-secretase yielded Aβ and a smaller 3 kDa fragment 
called as P3, respectively. Aβ42 plays a very important role in Alzheimer’s disease because 
the mutations occur in familial Alzheimer’s disease (FAD) leads to increase in the 
Aβ42/Aβ40 fragment ratio of peptide, Because these mutations leads to the C-terminal side 
of the Aβ sequence on APP[4]. Aβ, peptide the intracellular fragment that is produced by the 
action of γ-secretase processing of CTFα, CTFβ and CTFγ was not detected easily.  Aβ plays 
an important role in Alzheimer’s disease pathogenesis arises due to the mutations in the APP 
genes, PS1 genes and PS2 genes that are responsible for the Alzheimer’s disease, leads to 
increase in production of Aβ42 or total Aβ. Aβ Oligomer are neurotoxic in vitro and in vivo; 
because they lead to Alzheimer’s disease. 
 
Beta Secretase is the key enzyme that are responsible for the production of this 
potentially toxic peptide so it would be an important drug target for the treatment of 
Alzheimer’s disease. Beta secretase or BACE-1 or Memapsin-2 is a pepsin-like aspartic 
protease is considered to be a key target for the development of inhibitors of Alzheimer’s 
disease. The drugs those are available for the treatments of Alzheimer’s disease have 
limitations like they have low efficacy, have high cost and have severe side effects. the Small 
molecule that are obtained from  natural products are more  significant than  compared of  
chemically synthetic because they work as more  potential therapeutic agent  against many  
diseases[5]. Natural compounds may be important in treating the neurodegenerative diseases. 
So the Beta secretase is a validated drug target for Alzheimer’s disease drug discovery, 
because a particular inhibitor of the enzyme work as a potential drug molecule[6]. Potential 
inhibitors are identified by Insilco Virtual screening process that bind to beta secretase and 
the type of interaction and structural differences that exist between the beta secretase and 
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potential ligand molecule are required to recognize the interaction of potential ligand at the 
active site of beta secretase with optimization of rational drug candidates.  
 
 With the aim of identifying potential natural product inhibitors of beta secretase 
which can be effective or potential compound for the treatment of Alzheimer’s disease we 
have performed in silico virtual screening of a natural product data base that have 800 
compounds with different chemical property and entities. Beta secretase (PDB ID: 1FKN) 
was used in the Insilco virtual screening process, and the docking of compound were 
performed using Swiss dock server which is based on EADOCK DSS engine (combined with 
setup scripts for curating common problems and for preparing both the target protein and the 
ligand input files) considered as one of the best algorithm for small molecular conformational 
search to identify potential inhibitors molecules[7]. Then the compounds were selected based 
upon their binding energy and the top 50 compound that have more binding energy have been 
ranked protein-inhibitor complexes. The protein-inhibitor interactions into clusters and ligplot 
image of docked compound give some clues on various promising conformations that 
inhibitors can attain at the active site or bind in near the active site or in binding pocket of 
active site of beta secretase. After that the small potential molecule that is reported in this 
study can be further assayed for development into drugs. 
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2. REVIEW OF LITERATURE 
 
 
2.1. ALZHEIMER, S DISEASE 
                                                              
Alzheimer’s disease is a most common amyloid-associated disorder, irretrievable, 
progressive brain disorders that leads to change in nerve cells destroying the thinking, 
memory, remembering, and way of thinking and skills of individuals. Alzheimer’s disease 
patient have Insoluble, extracellular amyloid plaques, consist of fibrillar aggregates of the 
amyloid-beta (Aβ) peptide, a product of the proteolytic cleavage of β-amyloid precursor 
protein (APP). Alzheimer’s disease was first identified more than 100 years ago.  Generally 
Alzheimer’s disease appears after the age of 65 years & moreover a most common cause of 
dementia to old age people.  
 
The Alzheimer’s disease was named after Dr. Alois Alzheimer. Dr.  Alois Alzheimer 
noticed changes in the tissue of brain of a woman that died due to mental illness. He found 
that her brain have many abnormal clumps (amyloid plaques) and tangled bundles of fibers 
(neurofibrillary tangles). Plaques and tangles are responsible for the failure of brain because 
they prevent connection between the neurons due to which neuron cannot communicate 
between them and at last die that lead to Alzheimer’s disease. Deposition of Abnormal 
proteins in the form of amyloid plaques and tau tangles in the brain effect the efficiency of 
brain mainly in the part of hippocampus that is responsible for the memories[8]. Loss of 
neuron leads to reduction of brain which is the final stage of Alzheimer’s, disease [9, 10]. 
Alzheimer’s disease is misrepresented proteolytic processing of the amyloid beta precursor 
protein (APP) that results in the production and aggregation of neurotoxic forms of Aβ[11]. 
Neurons that degenerate in Alzheimer’s disease show increased impaired energy metabolism, 
oxidative damage, and disturbed or agitated cellular calcium homeostasis; so the appearance 
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of Aβ at this site may be an important instigator to predict these disease forming 
abnormalities[12]. 
 
 
                     
 
Figure 1: Shows the individual suffering from Alzheimer’s disease (a) according to age (b) according to gender 
& race. [Ref: SOURCE: National Academy on an Aging Society analysis of data from the 1994 
National Health Interview Survey of Disability, Phase I.] 
 
 
 
 
2.1.1. SYMPTOMS OF ALZHEIMER’S DISEASE  
 
Symptoms of Alzheimer’s disease causing Dementia that affect mental function, including: 
 failure of memory,  
 bad temper  
 Problems with reasoning and communication 
 poignant behavior or qualities 
 Thinking and judgment (cognitive skills) 
 complexity  in solving problems 
 Forgetting current events or conversations. 
 Taking longer time to perform more complicated activities. 
A B 
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 Alteration in sleep patterns and suddenly wakes up in the night. 
 Having Delusions, gloominess, disturbance. 
 Complexity doing basic responsibilities, for example preparing meals, selecting 
suitable clothing, and driving. 
 complexity in reading, understanding or writing 
 Aggressive behavior underprivileged judgment and failure of ability to recognize 
danger. 
 Using the incorrect statement, mispronouncing terms, speaking in perplexing 
sentences 
 Diminishing himself from social environment and people. 
The people suffering with severe Alzheimer’s disease can no longer: 
 recognize speech 
 distinguish family members 
 carry out necessary activities of daily living, like eating, dressing, and bathing 
A lot of other difficulty that people having this disease faces Incontinence, Swallowing 
troubles, lapses of memory and have troubles in finding the exact terms[13]. The most 
important effect of this disease is that public cannot remember information due to which 
difficulty comes because disturbance of brain neuron function usually involved in forming 
new memories.  
Warning signs of Alzheimer’s disease are:  
 Mystification with time or place.  
 Challenges in planning or solving problems. 
  Loss of remembrance that disrupts daily life. 
 Complexity carrying out familiar tasks at home, at work or at vacation.  
 New troubles with language in communication or writing. 
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 Difficulty in consideratation of visual images and spatial associations.  
 Pulling out from occupation or social activities.  
 Changes in mood and character and behavior. 
 Misplacing belongings and losing the capability to repeat steps. 
 
2.1.2. CAUSES OF ALZHEIMER’S DISEASE 
 
Amyloid precursor beta protein is a transmembrane protein. It is one of most abundant 
protein that is present in the central nervous system (CNS) of human[14]. It is also present in 
peripheral tissue and blood cells along with CNS. Two different pathway to metabolize 
Amyloid precursor beta protein include 
(a) non-amyloidogenic and  
(b) Amyloidogenic pathways.  
In non- amyloidogenic pathway enzyme γ-secretase slice Amyloid precursor beta protein, 
into  a soluble N-terminal fragment (sAPPα) and a C terminal fragment (C83), additionally 
cleaving  of C terminal domain was done by  α-secretase, that discharge  a C-terminal 
fragment of 3KDa (C3)[15, 16]. In Amyloidogenic pathway β-secretase cleaved Amyloid 
precursor beta protein and releases a smaller N-terminal fragment (sAPPβ) and a C-terminal 
fragment (C99)[17]. Then γ-secretase cleaves that part and produces the full-length β-
amyloid peptides (Aβ). 
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 Figure 2: shows non-amyloidogenic pathway and amyloidogenic pathway of sequential cleavage of app by β 
and γ-secretase. 
 
 
 
2.1.2.1. THE AMYLOID-Β CASCADE HYPOTHESIS:  
 
The amyloid-β cascade hypothesis was first described by Korczyn in 1990s. 
According to him gathering of β-amyloid peptides as neurofibrillary tangles and senile 
plaques in the brain, due to their amplified production or due to the decreased clearance from 
the brain, is responsible for pathogenetic characteristic of Alzheimer’s disease[18, 19]. Due 
to the accumulation of Aβ  peptide many proceedings that affects the neuron  occurs like 
increased oxidative stress inside the neuronal cell, dysfunction of mitochondria, unusual 
neuroinflammatory response, decreased neuroplasticity ,decreased neurotrophic support, and 
neurogenesis, hyperphosphorylation of TAU occurs, along with this there are  starts of 
apoptosis and disruption of calcium homeostasis occurs [20]. The Aβ peptide is a little sticky 
so that they form oligomers; these oligomers interrelate with neurons and microglia cells of 
brain triggering a sequence of negative events. The amyloid-β cascade hypothesis was based 
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mostly on in vivo studies and in vitro studies and then recognition of genetic mutations 
associated with early-onset of Alzheimer’s disease (i.e. mutation in the APP gene, and 
presenilin 1 and 2 genes)[21].  A mutation in APP genes leads to rise in production of Aβ and 
aggregation into oligomers, which is deposited as plaques. 
 
2.1.2.2 CHOLINERGIC HYPOTHESIS 
 
According to this hypothesis Alzheimer’s disease is caused by reduced synthesis of 
the neurotransmitter acetylcholine that are accountable for the transmittance of neuronal 
message from one neuron to another that are associated by synapses[22]. Neurofibrillary 
tangles formation takes place intracellular and sensile plaques formation takes place 
extracellular due to which they avoid neuron to communicate between them by forming 
aggregate of Aβ peptide. Some other cholinergic hypothesis beginning of large-scale 
aggregation of amyloid, leading to generalized neuroinflammation causing loss of neuron. 
 
2.1.2.3. GSK3β HYPOTHESIS 
 
Aβ peptides and hyperphosphorylated TAU plays a considerable role in the 
pathogenesis of Alzheimer’s disease. According to this hypothesis Neurofibrillary tangles 
and Aβ sensile plaques are produced by two different mechanism causing Alzheimer’s 
disease. A key enzyme GSK3β regulates cellular metabolism along with including 
phosphorylation of TAU protein[23]. Wnt signaling leads to the inactivation of GSK3β. 
usually GSK3β has been found in a hyperactive state that is accountable for 
hyperphosphorylation of TAU[20]. But in several cases GSK3β also regulates metabolism of 
amyloid precursor beta protein, and assist in amyloidogenic cleavage leads to overproduction 
12 
 
of Aβ, condensed neurogenesis and increased apoptosis[24]. Activation of GSK3β leads to 
neuronal changes and loss of neuronal cells that are observed in AD. But the inhibition of 
GSK3β activity protects in opposition to neuronal degeneration and death induced by Aβ and 
Tau hyperphosphorylation. 
 
2.1.3. PATHWAY OF ALZHEIMER’S DISEASE  
                      
  
Figure 3:  shows production of Aβ peptide and their fate in different compartment of cell. 
 
The above figure shows the sequential production of Aβ peptide from the APP protein by 
different sequential cleavage by different enzymes including alpha secretase, beta secretase, 
and gamma secretase. 
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2.2 ROLE OF BETA SECRETASE IN ALZHEIMER’S DISEASE 
   
BACE-1 or β-secretase, memapsin-2, or Aspartyl protease-2, is a single-membrane 
protein belongs to the Aspartyl protease class of enzyme accountable for the cleavage of 
app[25]. The cleavage of amyloid Beta precursor protein by beta secretase, consequences in 
the production of two peptide fragments Aβ40 and Aβ42[26]. Aβ42 is the most important 
species and are accountable for the neurotoxicity and amyloid plaque development in the 
brain that lead to Loss of neuron in the cortex and hippocampus section, guide to loss of 
memory and numerous defects in Alzheimer’s disease. Thus the Inhibition of beta secretase 
has emerged as an attractive therapeutic objective for Alzheimer’s disease[27]. During 1999–
2000, five teams concluded that the novel transmembrane Aspartyl protease BACE-1 (also 
named Memapsin-2 and Asp2) was the β-secretase. BACE-1 has two aspartic protease active 
site motifs, DTGS (residues 93–96) and DSGT (residues 289–292); BACE- 1 has an N-
terminal signal sequence (residues 1–21). Beta secretase has a single transmembrane domain 
near its C-terminus (residues 455–480) and a palmitoylated cytoplasmic tail. 
 
               
figure 4:  Ribbon diagram of beta secretase (PDB.ID 1FKN) showing active site containing Asp residues at 32 
and 228 position on amino acid length of protein[REF; protopedia life in 3d interactive encyclopedia of 
proteins, RNA, DNA and other molecule] . 
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Figure 5: generation of Aβ peptide by beta secretase (pdb.id 1fkn) (A to C). D shows sequential cleavage of 
app. [From: www.niapublications.org/pubs/unraveling/01.htm] 
 
 
β- Secretase cleaves Aβ at its N-terminus because of nucleophilic attack occurs at the 
active site of β-secretase. This β-site area which β-secretase binds to is made up of 
methionine-aspartate-alanine (MDA) residues. The aspartates molecule presents on β-
secretase combine to the aspartate residues of the β-site on APP (Asp672). This reaction is 
positive under acidic conditions that forcing N-terminus residues to split its bond with 
sAPPβ. The loop present in beta secretase assists in stabilization of protein with APP. If loop 
is absent then β-secretase is not capable to stabilize its interaction with APP and cleavage of 
APP will not be done. Active site of β- secretase is made up of two aspartate residues: Asp32 
and Asp228. The R groups of both the aspartates residues allowing for a nucleophilic attack 
to take place on the carbonyls[28]. So the molecule that have the resemblance more than APP 
A 
D 
C 
B 
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and having possessions to bind with the aspartate residues present at the active site of beta 
secretase may inhibit the enzyme to bind with the APP, may serve as a potential inhibitors of 
beta secretase. 
 
2.3. CURRENT THERAPEUTIC STRATEGY 
 
In present time there is no known treatment are available for treatment of Alzheimer’s 
disease. But with the help of medications we can control the agitation, depression or 
psychotic behavior.  
Currently five drugs are available that are approved by FDA and can be used as for 
the cure of Alzheimer’s disease. The Medicines are: Exelon® (rivastigmine); Cognex® 
(tacrine); Razadyne® (galantamine) and Aricept® (donepezil); these medicines help in 
inhibition of cholinesterase enzyme that is work as a neurotransmitter in synapses to assist 
neuron to communicate  between them, also help in regulation and interruption of symptoms 
of Alzheimer’s disease[29]. The individuals that are suffering from Alzheimer’s disease have 
very low levels of acetylcholine hormones, so these drugs help in communication between 
neuron. Acetyl cholinesterase inhibitors assist in sustain the rate at which acetylcholine 
hormone is broken and thereby increasing the concentration of acetylcholine in the brain 
uphold the balance of loss occurs due to death of cholinergic neurons[30]. These drugs also 
slowing degeneration of neuron and help in enhancement of function of brain also help in 
maintaining judgment, speaking skills, and remembrance, and also with certain behavioral 
problems. But the one thing is that these medicines have a few side effects like headache, 
decreased heart rate (bradycardia), loss of weight, decreased hunger, cramps take place in 
muscles, exhaustion, vomiting and production of increased gastric acid in elevated amount. 
The U.S. Food and Drug Administration approved a new drug for the treatment of 
16 
 
Alzheimer’s disease in 2006 was Namenda® (memantine) used to treat moderate 
Alzheimer’s disease. These drugs are administered orally. But when these drugs present in 
brain in surplus amount leads to death of neuronal cell, a process called excitotoxicity[31].  
Excitotoxicity leads to manufacture of large amount of glutamate as of overstimulation of 
glutamate receptors. Antipsychotic drugs are also helpful in treatment of Alzheimer’s disease 
by dropping aggression and obsession in individuals suffering from this disease[32]. In this 
study we aim to identify potential natural product inhibitors of beta secretase which can be 
additionally developed as drug to treat Alzheimer’s disease. BACE-1 will be a significant 
drug target for the production of inhibitors that lower Aβ.  Here; we have performed in silico 
virtual screening approach of a natural product database consists of 800 different chemical 
molecules. Beta secretase (PDB ID: 1FKN) was used in screening process, and docking 
studies to identify potential lead compounds. The  categorization of compound were done 
based upon their binding energy, and there type of interaction with the active site of beta 
secretase and top 50 ranked protein- inhibitor complexes were selected. 
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3 OBJECTIVES 
 
 Virtual screening of compound from natural product database. 
  Finding the best potential inhibitors based on energy calculations of their 
interactions. 
 Identification of potential binding pockets in the target enzyme. 
 Screening of selected compounds based on their binding near the active site of the 
enzyme. 
 Target enzyme-substrate docking to determine the binding energy of interaction. 
 Screening of selected compounds based on binding energy greater than enzyme-
substrate complex. 
 Analysis of the docking result for identification of potential inhibitor molecule. 
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4   PLAN OF WORK 
 
 
 
 
 
 
 
 
 
  
Retrieval of beta secretase structure from 
PDB (PDB id. 1fkn) 
 
Retrieval of small natural compound from 
natural product database 
 
Preparing the beta secretase molecule for 
docking using chimera 
 
Docking of small molecule retrieved from natural product with 
beta secretase using Swiss docking server  
 
Screening of docked molecule based on highest binding 
energy  
 
21 
 
 
 
  
      
 
 
 Identification of potential binding pockets in the target enzyme  
 
 
Selection of compounds based on their binding near the active 
site of the enzyme  
 
Docking of target enzyme-substrate to determine the binding 
energy of interaction  
 
Screening of selected compounds based on binding energy 
greater than enzyme-substrate complex  
 
Identification of residues involved in active site using ligplot  
 
Analysis of docking result for identification of potential 
inhibitor molecule. 
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5 MATERIALS AND METHODS 
5.1   MATERIALS: 
 
5.1.1   Requirement of files: 
 
 
  PDB file of beta secretase (PDB ID 1FKN). 
 Mol 2 file or ZINC AC file of ligand molecule.  
 CHIMEX files for input into UCSF chimera.  
 PDB file of docked molecule for the identification of type of interaction into 
ligplot. 
 
5.1.2 Requirement of Software’s: 
 
 Chimera 1.6.1 
 Hex software 6.1 
  Ligplot  
 
5.1.3 Requirement of online server’s: 
 

 http://www.rcsb.org/ 
 http://www.msdiscovery.com/natprod.html 
 http://www.swissdock.ch/ 
 http://projects.biotec.tu-dresden.de/metapocket/ 
 http://dogsite.zbh.uni-hamburg.de/ 
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5.2 METHODS: 
 
 
In this Insilco based screening, we have selected beta secretase (PDB ID 1FKN) which 
plays a critical role in the development of amyloid beta peptide that are responsible for main 
cause of Alzheimer’s disease.  
 
5.2.1 Preparation of protein molecule: 
 
 
 Beta secretase (PDB ID 1FKN) were downloaded from the protein data bank 
(http://www.rcsb.org/pdb), already complexed with the inhibitors. Beta-secretase is a 
membrane-associated aspartic protease made up of two chain A& B, 391 long amino acid 
sequence protein. Then this PDB file of beta secretase is opened in chimera 1.6.1 where the 
inhibitor molecule that is complexed with beta secretase was removed and we get pure form 
of beta secretase. Then pdb file of this molecule was saved for further use in docking process. 
 
5.2.2 Selection of ligand molecule: 
 
Ligand molecule was selected from natural product database 
(http://www.msdiscovery.com/natprod.html), containing 800 chemical entities obtained from 
different natural sources. These entities have flavonoids, alkaloids, phenones, terpenes, 
chalones, sterols, comurins compound some obtained from plant and microbes. 
 
5.2.3. Docking: 
In this study we have used swissdock server (http://www.swissdock.ch/) for protein-
ligand docking. It is an online web server based on EADock DSS, used for protein ligand 
docking. 
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5.2.3.1. Inputs: 
 
 In swissdock server we have to follow just three steps to access docking. The sample 
files can be directly uploaded into the form simply by clicking on a provided link in the 
swissdock server. 
 
5.2.3.1.1. Selection of target protein: 
 
Target protein was loaded by just providing the PDB ID or protein FASTA sequence 
or by URL or by uploading as the PDB files that was saved earlier after processed in chimera. 
When we uploading the target protein file it takes few seconds to upload because between 
that time server processed the uploaded protein by calculating on the basis of CHARMM 
force field. 
 
5.2.3.1.2. Selection of ligand molecule: 
Ligand molecule can be selected either by giving ligand name or by ZINC accession 
code or by categories like  scaffolds, side chains or by providing URL or by preprocessed 
ligand molecule as mol2 file.  
 
5.2.3.1.3. Docking parameters: 
 
According to our requirement we can select docking parameters like type of docking 
that to start between uploaded ligand and target molecule like fast, accurate or very fast. Then 
we have selected accurate mode of docking that take desired docking time, number of 
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minimization steps to relax ligand and number of predicted binding modes. Select the region 
that containing the active site/binding site of beta secretase to prevent whole scanning of 
ligand molecule for docking to target protein.  
 
5.2.3.2. Outputs: 
 
When the docking is completed the output file is downloaded from the link provided 
by the web server in the form of CHIMEX format after a docking assay has been submitted, 
The  docking result web page gives image of docked molecule in  JMOL form. From that we 
can visualize or predict the mode of binding of ligand molecule with the target protein. We 
can also visualize this mode of binding by opening the downloaded CHIMEX file into UCSF 
chimera. Web page also provide result in zip file format that contain PDB file of docked 
complex of target with ligand and also contains mode of binding in dock format. 
 
 
5.2.4. Prediction of binding site of protein: 
 
Binding site of beta secretase was predicted by mate pocket 2.0 
(http://projects.biotec.tu dresden.de/METAPOCKET/). Mate pocket 2.0 is an online server 
used for prediction of number of binding site/active site present in a protein by using different 
active site prediction tools like Q site finder, LIGSITE, PASS11, POCASA, FPOCKET, 
SURFNET, GHECOM, ConCAVITY.  There are 10 different binding pockets are present in 
the beta secretase to which the ligand molecule bind. Meta pocket 2.0 predicted the top three 
potential binding pockets containing amino acid residues, all atoms that are present in the 
beta secretase. We can visualize the protein structure and binding mode in JMOL format. 
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Active site of beta secretase contains two aspartate residues situated at position 32 and 228 
position of amino acid sequence. 
 
5.2.5. Analysis and active site prediction: 
 
The active site/ binding site of beta secretase was also predicted by DogSiteScorer 
(http://dogsite.zbh.uni-hamburg.de/). It is used for analysis and prediction for protein 
druggability. DoGSite predicted that beta secretase is made up of 10 pockets and 14 different 
sub pockets, also predict the size, shape, global properties, and chemical features of pockets, 
volume, depth, surface, residues, as well as functional groups present in the pockets, and give 
a Simple Score for each pocket between zero and one to predict druggability. According to 
this prediction the molecule that has score close to one having the property to be worked as 
potential inhibitors of beta secretase. 
 
 
5.2.6. Structural analysis of docked molecule: 
 
The binding energy of docked molecule was obtained from web server of swissdock 
by just clicking on the link provided on the bottom of web server and then the saved 
CHIMEX file was opened into chimera for the structural analysis of docked molecule. By 
using UCSF chimera we convert the CHIMEX file into PDB file to understand mode of 
interaction between the target and ligand molecule. 
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5.2.7. Ligplot 
 
Ligplot is software, used to study interactions between the protein and the ligand 
molecule in the protein-ligand complex. Saved PDB file of docked molecule from UCSF 
chimera was opened into Ligplot by following these steps. 
 Open the PDB file saved from UCSF chimera.  
 Select the protein and ligand chain. 
 Go to run button  
The image shows type of interaction like hydrogen bonding, hydrophobic interaction 
to or near the active site of protein. 
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6 RESULTS 
In this study beta secretase (PDB ID 1FKN) was docked with 800 compound obtained 
from natural product database. The results of structure based virtual screening revealed the 
mode and type of interaction of ligand molecule with the beta secretase (target) protein 
molecule. Here we have selected molecules based on their binding energy.   
6.1. BEST POTENTIAL INHIBITORS BASED ON ENERGY CALCULATIONS OF 
THEIR INTERACTIONS. 
 
Table 1 shows the structure properties and docking statics of top 44 compounds. 
 
Sr.
no. 
 
Name of 
compound 
 
Structure 
 
Source 
 
Mol. wt. 
 
Binding 
energy 
 
1. 
 
NETILMICIN 
SULFATE  
 
  
 
semisenthic 
(sch-20569)  
 
 
671.7354  
 
 
-11.51 
 
2. 
 
PUROMYCIN  
HYDROCHLORIDE 
 
 
streptomyces       
alboniger 
 
544.4423 
 
-11.31 
 
3. 
 
ANTIMYCIN A 
 
 
Streptomyces spp 
 
534.6118 
 
 
-11.27  
 
 
4. 
 
ERYTHROMYCIN  
 
   
 
Streptomyces 
erythreus  
 
 
733.9454  
 
 
-10.99 
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5. 
 
PANTETHINE  
 
 
 
semisynthetic  
 
 
554.73  
 
 
-10.96  
 
 
6. 
 
SPERMINE  
 
 
 
all animal tissue, 
fungi 
 
 
202.3455  
 
 
-10.92  
 
 
7. 
  
SPERMIDINE 
TRIHYDROCHLOR
IDE 
 
 
animal tissue and 
coprinus comatus  
 
 
254.6325  
 
 
-10.78  
 
 
8. 
 
CEPHALOSPORIN 
C     SODIUM 
 
 
  
cephalosprium 
acremonium 
 
427.4039  
 
 
-10.66  
 
 
9. 
 
CARNOSINE  
 
 
 
mammalian 
skeletal muscle  
 
 
226.2369  
 
 
-10.36  
 
 
10. 
 
LUNARINE  
 
 
 
lunaria spp  
 
 
437.5435  
 
-10.26  
 
 
11. 
 
 
CYCLOSPORINE  
 
 
 
tolypocladium 
inflatum  
 
 
1202.642  
 
 
-10.03  
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12
. 
 
 
APRAMYCIN  
 
 
 
streptomyces 
tenebrarius, 
saccharomyces 
porispora hiltus  
 
 
 
539.587
8  
 
 
 
-
10.0
1  
 
 
13
. 
 
CADAVERINE 
TARTRATE 
 
 
 
 
putrifaction of 
lysine  
 
 
 
224.215
4  
 
 
 
-9.75  
 
 
 
14
. 
 
 
PUTRESCINE 
DIHYDROCHLORIDE  
 
 
 
 
catabolism of 
ornithine  
 
 
 
161.075
6 
 
 
 
-9.55  
 
 
 
15
. 
 
 
ACARBOSE  
 
 
 
 
actinoplanes 
spp  
 
 
 
645.617
4 
 
 
 
-9.52  
 
 
 
16. 
 
 
GENETICIN  
 
 
 
 
micromonospor
a species  
 
 
 
692.717
7  
 
 
 
-9.43  
 
 
 
17. 
 
 
MELEZITOSE  
 
 
 
 
honey & plant 
exudates  
 
 
 
504.446
1  
 
 
 
-9.42  
 
 
 
18. 
 
 
ORNITHINE  
 
 
 
 
widespread in 
nature  
 
 
 
132.163
6  
 
 
 
-9.38  
 
 
 
19. 
 
 
CYSTINE 
 
 
widespread in 
plants and 
animals  
 
 
 
240.301
5  
 
 
 
-9.37  
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20. 
 
 
AMYGDALIN 
 
 
 
rosaceae spp  
 
 
 
457.438
3  
 
 
 
-9.23  
 
 
 
21. 
 
 
MUPIROCIN 
 
 
 
pseudomonas 
fluorescens; brl-
4910a  
 
 
 
500.635
2  
 
 
 
-9.21  
 
 
 
22. 
 
 
3- HYDROXYTYRAMINE 
 
 
 
synthetic  
 
 
 
153.182
4  
 
 
 
-9.13  
 
 
 
23. 
 
 
SEROTONIN 
HYDROCHLORIDE 
 
 
 
CNS, GI tract, 
all animals, 
many 
mushrooms & 
plants  
 
 
 
212.680
9 
 
 
-9.04  
 
 
 
24. 
 
 
GENTAMICIN 
SULFATE 
 
 
 
micromonospor
a spp  
 
 
 
575.683
7  
 
 
 
-9.03  
 
 
 
25. 
 
 
1R,2S 
PHENYLPROPYLAMIN
E  
 
 
 
 
ephedra 
vulgaris 
(mahuang)  
 
 
 
151.210
1  
 
 
 
-8.98  
 
 
 
26. 
 
 
THIAMINE  
 
 
 
 
rice husks, 
wheat germ, 
yeast  
 
 
 
337.273
5  
 
 
 
-8.94  
 
 
 
27. 
 
 
BEKANAMYCIN 
SULFATE 
 
 
 
semisynthetic; 
streptomyces 
kanamyceticus; 
nk-1006  
 
 
 
581.600
6 
 
 
-8.93  
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28. 
 
 
DIOSMIN  
 
 
 
 
zanthoxylum 
avicennae  
 
 
 
608.558
2  
 
 
 
-8.92  
 
 
 
29. 
 
 
HISTAMINE 
DIHYDROCHLORIDE 
 
 
 
claviceps 
purpurea  
 
 
 
184.069
5  
 
 
 
-8.56  
 
 
 
30. 
 
 
AVOCADYNE  
 
 
 
 
persea spp  
 
 
 
284.442
8  
 
 
 
-8.38  
 
 
 
31. 
 
 
MIMOSINE 
 
 
Mimosa and 
Leucena spp 
 
 
 
198.1799 
 
 
 
-8.33 
 
 
32. 
 
 
TETRACYCLINE 
HYDROCHLORIDE 
 
 
 
 
streptomyces 
spp  
 
 
 
 
480.9062  
 
 
 
-8.25  
 
 
 
33. 
 
 
    EMETINE  
 
 
 
 
uragoga 
ipecacuanha  
 
 
 
553.5751 
 
 
-8.23  
 
 
 
34. 
 
 
KANAMYCIN A 
SULFATE 
 
 
 
streptomyces 
kanamyceticus  
 
 
 
582.5854  
 
 
 
-8.23  
 
 
 
35. 
 
 
alpha-
DIHYDROGEDUNOL  
 
 
 
 
derivative  
 
 
 
486.6109  
 
 
 
-8.23  
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36. 
 
 
TRYPTOPHAN 
 
 
 
many plants, 
animal protein  
 
 
 
204.2305 
 
 
 
-8.21 
 
 
37. 
 
 
GENTAMICIN 
SULFATE 
 
 
 
 
micromonospor
a spp  
 
 
 
575.6837  
 
 
 
-8.19  
 
 
 
38. 
 
 
BEKANAMYCIN 
SULFATE 
 
 
 
semisynthetic; 
streptomyces 
kanamyceticus; 
nk-1006  
 
 
 
581.6006  
 
 
 
-8.17  
 
 
 
39. 
 
 
ARECOLINE 
HYDROBROMIDE 
 
 
 
 
betel nuts (arica 
catechu)  
 
 
 
236.1103  
 
 
 
-8.12  
 
 
 
40. 
 
 
CANAVANINE  
 
 
 
 
canavalia 
ensiformis  
 
 
 
176.1764 
 
 
-8.10  
 
 
 
41. 
 
 
ALOIN  
 
 
 
 
aloe  
 
 
 
434.4035  
 
 
 
-8.09  
 
 
 
42. 
 
 
ALLIIN  
 
 
 
 
allium species  
 
 
 
177.2235  
 
 
 
-8.09  
 
 
 
43. 
 
 
3-AMINO-beta-PINENE  
 
 
 
 
derivative  
 
 
 
187.7147  
 
 
 
-8.09  
 
36 
 
 
 
44. 
 
 
NARINGIN  
 
 
 
 
citrus spp  
 
 
 
580.5477  
 
 
 
-8.06  
 
 
 
 
6.2. IDENTIFICATION OF POTENTIAL BINDING SITE IN THE TARGET ENZYME:  
 
Active site of beta secretase is made up of two aspartate residues situated as position 
32 and 228 of the amino acid sequence of protein. Active site/ binding site of beta secretase 
were predicted by METAPOCKET 2.0 servers and DOGSITE scorer server. METAPOCKET 
2.0 is an online server where we have uploaded PDB file of beta secretase then it gives the 
top three potential binding sites containing amino acid residues that are present to the active 
site or near the active site of target protein, it also tells all no. of amino acid present in each of 
top three potential binding sites. METAPOCKET 2.0 servers uses 10 active site prediction 
tools including Q site finder, pass11, LigsiteCS, GHECOM, POCASA, Fpocket, SURFNET, 
ConCavity and predict top three potential binding pockets.  
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Figure 6:  show JMOL view of protein structure and binding sites (pdb.id 1fkn) predicted by METAPOCKET 
2.0. 
 
 
 The above image belongs to beta secretase predicted by METAPOCKET 2.0 shows 
pockets (binding sites) and sub pockets. Active site of beta secretase contains Asp 32 and Asp 
228(fig.8.). The β hairpin loop over the active site, known as the "flap “and the 10s loop also 
contains within it a glycine residue (gly11) with which the substrate can form a hydrogen 
bond. 
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Figure 7: Ribbon diagram of beta secretase (pdb.id 1fkn) showing active site containing Asp residues at 32 and 
228 positions on amino acid length of protein. 
 
 
Binding site of beta secretase was also predicted by DOGSITE scorer, an online 
server used for structural analysis and active site prediction of beta secretase, also used to 
check protein druggability. DoGSite predicted that beta secretase is made up of 13 different 
pockets (binding site) and 10 different sub pockets, also predict the size, shape, global 
properties, and chemical features of pockets, volume, depth, surface, residues, as well as 
functional groups present in the pockets, and give a Simple Score for each pocket between 
zero and one to predict druggability. According to this prediction the molecule that has score 
close to one having the property to be worked as potential inhibitors of beta secretase. From 
this table the ligand molecules that have score close to one and those bind to the active site or 
near the active site can be serving as potential inhibitors of beta secretase.    
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Figure 8: DoGSite predicted (a) all pockets and (b) only PO present in beta secretase (PDB id 1fkn).  
 
 
 
Table 2: Illustrates All Binding Site (Pockets) and Their Drug Score of Beta Secretase (PDB Id 1fkn). 
 
       
 
 
 
 
 
 
A 
B 
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Table 3: Illustrates all sub pockets and their drug score of beta secretase (pdb id 1fkn). 
      
 
                               
 
6.3. SCREENING OF SELECTED COMPOUNDS BASED ON THEIR BINDING 
NEAR THE ACTIVE SITE OF THE ENZYME:  
  
 By following METAPOCKET 2.0 and DoGSite scorer we have selected following 
compound that bind to the active site or near the active site of beta secretase. These 
compounds comes in top three binding pockets having druggability score close to one and 
bind to the active site or near the active site of beta secretase enzyme. 
 
Table 4: Illustrate ligand molecule bind to or near the active site of beta secretase  
Sr.No
. 
Molecule bound to 
both  
asp 32 & asp 228 
 
molecule 
bound to  
either asp 32 or 
asp 228 
 
molecule bind 
near the active   
site 
 
molecule bind near 
the active site by 
hydrophobic 
interaction 
1.  
SPERMINE 
 
 
3- AMINO 
BETEPIENENE  
 
 
ACARBOSE  
 
 
ALLOIN  
 
 
 
2.  
 
SPERMIDINE 
HYDROCHLORIDE 
 
 
ARECOLINE 
HYDROBROMID
E  
 
 
AMYGDLIN  
 
 
Alpha- 
DIHYDROGLUDENO
L  
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3. 
 
3- HYDROXY 
TYRAMINE  
 
 
THIAMINE  
 
 
ANTIMYCIN A  
 
 
APEGENIN  
 
 
4. 
 
1R,2S 
PHENYLPROPYLAMIN
E  
 
  
APRAMYCIN  
 
 
 BEKANAMYCIN  
SULPHATE  
 
 
5.  
 
TRYPTOPHAN 
 
  
ATROPINE 
SULPHATE  
 
 
 
CITRININ  
 
 
6. 
 
SEROTONIN 
HYDROCHLORIDE 
 
  
AVOCADYNE  
 
 
CRUSDESONE  
 
 
7. 
 
PUTRESEDINE 
HYDROCHLORIDE 
 
  
CANVELATOXIN  
 
 
 
DIFLUNISAL  
 
 
8. 
 
MIMOSINE  
 
  
CENEIOLE  
 
 
ERGOSTEROL  
 
 
9. 
 
CYSTINE 
 
  
CYCLOSPORINE  
 
 
GENTAMYCIN 
SULPHATE  
 
 
10. 
 
CARNOSINE 
 
  
CEPHALOSPORIN 
C SODIUM  
 
 
KANAMYCIN 
SULPHATE  
 
 
11. 
 
CANAVENINE 
 
  
DIOSMIN  
 
 
PUROMYCIN 
HYDROCHLORIDE  
 
 
12. 
 
CADAVARINE 
TARTERATE 
 
  
EMETINE  
 
 
 
13. 
   
ERYTHROMYCIN  
 
 
 
14. 
   
GENETECIN  
 
 
 
15. 
   
LUNARINE  
 
 
 
16.  
   
MELEZITOSE  
 
 
 
17. 
   
MUPIROCIN  
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18. 
   
NARINGIN  
 
 
 
19.  
   
NELEMICIN 
SULPHATE  
 
 
 
20. 
   
ORNITHINE  
 
 
 
21. 
   
PANTETHINE  
 
 
 
22. 
   
QUERCETIN  
 
 
 
23. 
   
TETRACYCLINE 
HYDROCHLORID
E  
 
 
  
 
 
6.4. DOCKING OF TARGET ENZYME-SUBSTRATE: 
  
 Bate secretase (PDB ID 1FKN) were docked with amyloid beta precursor protein 
E2 binding domain (PDB ID 3NYL) by using hex 6.1 tool, and binding energy was 
calculated. Then the pdb file was opened into chimera to visualize the type of interaction 
between the target protein and ligand molecule. Binding energy calculated by hex was – 8.84. 
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Figure 9: Docked image of beta secretase (PDB ID 1FKN) with human amyloid precursor protein E2 domain 
(PDB ID 3NYL). 
 
 
 
6.5 SCREENING OF SELECTED COMPOUNDS BASED ON BINDING ENERGY: 
 
 Further we have screened compound that have energy greater than target enzyme- 
substrate complex and also  they  bind to the active site of beta secretase, to identify potential 
inhibitors of beta secretase that prevent formation of amyloid beta peptide, main cause of 
Alzheimer’s disease. Selected compound that have energy greater than target enzyme- 
substrate complex have higher affinity to bind with the target beta secretase more than normal 
amyloid beta precursor protein and it also bind to the active site of beta secretase.  
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Table 5: illustrate binding mode and binding energy of compound having energy greater than target- substrate 
complex.  
Sr. no. Name of compound Binding 
energy 
                Binding site 
 
1. 
 
PANTETHINE  
 
 
-10.96  
 
 
Bind near the active site  
 
 
2. 
 
SPERMINE  
 
 
-10.92  
 
 
Bind to both Asp 32 & Asp 228  
 
 
3. 
 
SPERMIDINE 
TRIHYDROCHLORIDE  
 
 
-10.78  
 
 
Bind to both Asp 32 & Asp 228  
 
 
4. 
 
CEPHALOSPORIN C SODIUM 
 
 
-10.66  
 
 
Bind near the active site  
 
 
5. 
 
CARNOSINE  
 
 
-10.36  
 
 
Bind to both Asp 32 & Asp 228  
 
 
6. 
 
LUNARINE 
 
 
-10.26  
 
 
Bind near the active site  
 
 
7. 
 
CYCLOSPORINE  
 
 
 
-10.03  
 
 
Bind near the active site  
 
 
8. 
 
CADAVERINE TARTRATE 
 
 
-9.77  
 
 
Bind to both Asp 32 & Asp 228  
 
 
9. 
 
PUTRESCINEDIHYDROCHLORIDE  
 
 
-9.55  
 
 
Bind to both Asp 32 & Asp 228  
 
 
10. 
 
ACARBOSE 
 
 
-9.52  
 
 
Bind near the active site  
 
 
11. 
 
MELEZITOSE 
 
 
-9.42  
 
 
Bind near the active site  
 
 
12. 
 
ORNITHINE  
 
 
-9.38  
 
 
Bind near the active site  
 
 
13.  
 
CYSTINE  
 
 
-9.37  
 
 
Bind to both Asp 32 & Asp 228  
 
 
14. 
 
AMYGDALIN  
 
 
-9.23  
 
Bind near the active site  
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15. 
 
MUPIROCIN  
 
 
-9.21  
 
 
Bind near the active site  
 
 
16. 
 
3- HYDROXYTYRAMINE  
 
 
-9.13  
 
 
Bind to both Asp 32 & Asp 228  
 
 
17. 
 
SEROTONIN HYDROCHLORIDE 
 
 
-9.04  
 
 
Bind to both Asp 32 & Asp 228  
 
 
18. 
 
1R,2S PHENYLPROPYLAMINE 
 
 
-9.00  
 
 
Bind to both Asp 32 & Asp 228  
 
 
19. 
 
THIAMINE  
 
 
-9.00  
 
 
Bind to  Asp 32  
 
 
 
 
6.6 ANALYSIS OF THE DOCKING RESULT FOR IDENTIFICATION OF 
POTENTIAL INHIBITOR MOLECULE: 
 
 To identify potential inhibitors from the docked compound we have used ligplot. 
When we have opened the PDB file of docked molecule into ligplot it gives the mode of 
interaction like hydrogen binding, hydrophobic interaction, VANDERWALL forces etc and 
residues involved in the binding between target beta secretase and ligand molecule. starting 
that we can identify that the residues that bind to the active site or near the active site to target 
bate secretase protein can prevent the interaction between target protein and amyloid beta 
precursor protein by which the production of amyloid beta peptide stop. Here we have 
selected top five compounds that have binding energy more than target enzyme- substrate 
complex and they bind at the active site to the both residues of Asp 32 and Asp 228 of beta 
secretase. So these compounds may be effective inhibitors of beta secretase to prevent 
formation of amyloid beta peptide, responsible for the main cause of Alzheimer’s disease.   
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 Figure 10: Shows docked image of SPERMINE with beta secretase (pdb.id. 1fkn). 
 
                   
Figure 11: Interaction of SPERMINE molecule with beta secretase (pdb.id. 1fkn) had shown by ligplot. 
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Figure 12: Shows docked image of SPERMIDINE TRIHYDROCHLORIDE with beta secretase (pdb.id. 1fkn). 
 
 
                           
Figure 13: Interaction of SPERMIDINE TRIHYDROCHLORIDE molecule with beta secretase (pdb.id. 1fkn) 
has shown by ligplot. 
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 Figure 14: Shows docked image of PANTETHINE with beta secretase (pdb.id. 1fkn). 
 
                               
  Figure 15: Interaction of PANTETHINE molecule with beta secretase (pdb.id. 1fkn) has shown by ligplot. 
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Figure 16: Shows docked image of CARNOSINE with beta secretase (pdb.id. 1fkn). 
 
            
Figure 17: Interaction of CARNOSINE molecule with beta secretase (pdb.id. 1fkn) has shown by ligplot. 
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Figure 18: Shows docked image of CADAVERINE TARTRATE with beta secretase (pdb.id. 1fkn). 
                          
Figure 19: Interaction of CADAVERINE TARTRATE molecule with beta secretase (pdb.id. 1fkn) has shown 
by ligplot. 
 
 
 
 
51 
 
 
 
   
  CHAPTER 7 
                  DISCUSSION   
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
7 DISCUSSIONS: 
  
 Alzheimer’s disease is a most common amyloid-associated disorder, unalterable, 
progressive brain disorders that leads to alter in nerve cells destroying the assessment, 
remembrance, identification, interpretation and skills of persons. The symptom of 
Alzheimer’s, disease generally appears in the persons having age more than 65 years. 
Alzheimer’s disease uncomplaining have Insoluble, extracellular amyloid plaques, 
consist of fibrillar aggregates of the amyloid-beta (Aβ) peptide, a result of the 
proteolytic cleavage of β-amyloid precursor protein (APP). The Alzheimer’s disease 
pathological hallmarks consist of existence of extracellular senile plaques and 
intracellular neurofibrillary tangles (NFT).Because neurofibrillary tangles are 
intracellular fibrillar aggregates of the microtubule-associated protein tau that 
demonstrate oxidative modifications and hyperphosphorylation. The drugs those are 
accessible for the treatments of Alzheimer’s disease have limitations like they have low 
usefulness, have high charge and have brutal side effects. The two enzymes, γ- 
secretase and β-secretase (BACE-1 or Memapsin-2), are accountable for the sequential 
cleavage of APP for the creation of Aβ peptide. The cleavage of APP by BACE-1 leads 
to construction of two peptide fragments Ab40 and Ab42. Ab42 is considered to be 
accountable for the neurotoxicity and amyloid plaque creation in Alzheimer’s disease 
(AD). Therefore BACE-1 will be a significant drug article for the production of 
inhibitors that lower Aβ. We aspire to recognize prospective natural product inhibitors 
of beta secretase which can be additionally developed as drug to care for Alzheimer’s 
disease. In this study we performed in silico virtual screening approach of a natural 
product database consists of 800 diverse chemical molecules. Beta secretase (PDB ID: 
1FKN) was used in screening procedure, and docking studies to identify potential lead 
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compounds. The molecules were selected based on their binding energy exposed that 
they have higher affinity to bind with target enzyme beta secretase. Active site of beta 
secretase is made up of two aspartate residues located as position 32 and 228 of the 
amino acid sequence of protein. Active site/ binding site of beta secretase were 
predicted by METAPOCKET 2.0 servers and DOGSITE scorer server.  Binding site of 
beta secretase was also predicted by DOGSITE scorer, to verify protein druggability. 
DoGSite predicted that beta secretase is made up of 13 diverse pockets (binding site) 
and 10 dissimilar sub pockets, and give a Simple Score for every pocket between zero 
and one to predict druggability. According to this prediction the molecule that has 
score close to one having the property to be worked as potential inhibitors of beta 
secretase. So ligand molecules that have score close to one and those bind to the active 
site or near the active site can be serving as potential inhibitors of beta secretase. Bate 
secretase (PDB ID 1FKN) were docked with amyloid beta precursor protein E2 binding 
domain (PDB ID 3NYL) by using hex 6.1 tool, and binding energy calculated by hex 
was – 8.84. Further we have selected compound that have binding energy greater than 
binding energy of target- substrate complex and that bind to the active site or near the 
active site may work as a potential inhibitors of beta secretase.potential inhibitors from 
the docked compound was identified by using ligplot. From that we can identify that 
the residues that bind to the active site or near the active site to target bate secretase 
protein can prevent the interaction between target protein and amyloid beta precursor 
protein by which the production of amyloid beta peptide stop. At last we have selected 
top five compounds that have binding energy more than target enzyme- substrate 
complex and they bind at the active site to the both residues of Asp 32 and Asp 228 of 
beta secretase. Docking analysis has revealed involvement of hydrogen and 
hydrophobic interactions between the potential inhibitor molecules and the target 
54 
 
enzyme. Finally based on the binding energy and binding sites we have identified 
SPERMINE, SPERMIDINE TRIHYDROCHLORIDE, PANTETHINE, 
CARNOSINE, and CADAVERINE TARTRATE to be the top potential inhibitors 
against beta secretase. So these compounds may be effective inhibitors of beta 
secretase to prevent formation of amyloid beta peptide, responsible for the main cause 
of Alzheimer’s disease. So the potential inhibitors may be SPERMINE, SPERMIDINE 
TRIHYDROCHLORIDE, PANTETHINE, CARNOSINE, and CADAVERINE 
TARTRATE molecules selected from natural product database. 
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8 CONCLUSIONS  
Alzheimer’s disease is a most common amyloid-associated disorder, unalterable, 
progressive brain disorders that leads to alter in nerve cells destroying the thinking, 
remembrance, identification, interpretation and skills of persons. The neuropathological 
hallmarks of AD consist of occurrence of senile plaques (NP) and neurofibrillary tangles 
(NFT). Amyloid Beta precursor protein cleaving enzyme (BACE-1) belongs to the Aspartyl 
protease family, and it is accountable for the processing of the amyloid Precursor protein 
(APP). The cleavage of APP by BACE-1 leads to creation of two peptide fragments Ab40 
and Ab42. Ab42 is deliberation to be accountable for the neurotoxicity and amyloid plaque 
formation in Alzheimer’s disease (AD). In this study we have done virtual screening of 
compound retrieved from natural product database and docking study with beta secretase 
revealed that the natural compound having highest binding energy and bind to or near the 
active site can block the enzyme to bind with the substrate and thus work as a potential 
inhibitors of beta secretase for the treatment of Alzheimer's disease.  Docking analysis has 
revealed involvement of hydrogen and hydrophobic interactions between the potential 
inhibitor molecules and the target enzyme. Finally based on the binding energy and binding 
sites we have identified SPERMINE, SPERMIDINE TRIHYDROCHLORIDE, 
PANTETHINE, CARNOSINE, and CADAVERINE TARTRATE to be the top potential 
inhibitors against beta secretase. 
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9 FUTURE WORKS 
 
In this all above written conclusion are recognized by the assist of hopeful, consistent 
equipment and software of computational biology. In this current period of Insilco, each and 
every work is initially checked by Virtual screening or Insilico designing, after that we do 
invitro and invivo investigation. The future work of this study will be to do molecular 
dynamic simulation of the beta secretase inhibitors compound to study its behavior in real 
system. In vitro and in vivo validation will be required so that the selected inhibitors can be 
used as a potential drug candidate for inhibition of amyloid beta peptide formation which is 
the main cause of Alzheimer’s disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 10 
 
                   REFERENCES 
 
 
 
 
 
 
 
 
 
60 
 
10 REFERENCES 
 
1. Schellenberg, G.D., et al., The genetics of Alzheimer's disease. Biomedicine & 
Pharmacotherapy, 1989. 43(7): p. 463-468. 
2. Armstrong, R.A., et al., Relationships between β-amyloid (Aβ) deposits and blood 
vessels in patients with sporadic and familial Alzheimer's disease. Neuroscience 
Letters, 1996. 207(3): p. 171-174. 
3. Coughlan, C.M. and K.C. Breen, Factors influencing the processing and function of 
the amyloid β precursor protein—a potential therapeutic target in Alzheimer's 
disease? Pharmacology & Therapeutics, 2000. 86(2): p. 111-144. 
4. Citron, M., Emerging Alzheimer’s disease therapies: inhibition of β-secretase. 
Neurobiology of Aging, 2002. 23(6): p. 1017-1022. 
5. Graham, J.G. and N.R. Farnsworth, 3.04 - The NAPRALERT Database as an Aid for 
Discovery of Novel Bioactive Compounds, in Comprehensive Natural Products II, M. 
Editors-in-Chief:  Lew and L. Hung-Wen, Editors. 2010, Elsevier: Oxford. p. 81-94. 
6. Willem, M., S. Lammich, and C. Haass, Function, regulation and therapeutic 
properties of β-secretase (BACE1). Seminars in Cell & Developmental Biology, 
2009. 20(2): p. 175-182. 
7. Friedman, R., K. Boye, and K. Flatmark, Molecular modelling and simulations in 
cancer research. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013. 
1836(1): p. 1-14. 
8. Dickson, T.C. and J.C. Vickers, The morphological phenotype of β-amyloid plaques 
and associated neuritic changes in Alzheimer’s disease. Neuroscience, 2001. 105(1): 
p. 99-107. 
61 
 
9. Vogels, O.J.M., et al., Cell loss and shrinkage in the nucleus basalis Meynert complex 
in Alzheimer's disease. Neurobiology of Aging, 1990. 11(1): p. 3-13. 
10. Fraser, P.E., L. Lévesque, and D.R. McLachlan, Biochemistry of Alzheimer's disease 
amyloid plaques. Clinical Biochemistry, 1993. 26(5): p. 339-349. 
11. Yates, E.A., et al., Specific Domains of Aβ Facilitate Aggregation on and Association 
with Lipid Bilayers. Journal of Molecular Biology, (0). 
12. Mattson, M.P., Perturbed calcium homeostasis in neurodegenerative disorders, in 
Advances in Cell Aging and Gerontology, P.M. Mark, Editor 2001, Elsevier. p. 29-54. 
13. Arbus, C., et al., Symptômes dépressifs dans la maladie d' Alzheimer :résultats 
préliminaires de l'étude REAL.FR. La Revue de Médecine Interne, 2003. 24, 
Supplement 3(0): p. 325s-332s. 
14. White, A.R., et al., Diverse fibrillar peptides directly bind the Alzheimer’s amyloid 
precursor protein and amyloid precursor-like protein 2 resulting in cellular 
accumulation. Brain Research, 2003. 966(2): p. 231-244. 
15. Lim, K.H., et al., Characterizations of distinct amyloidogenic conformations of the Aβ 
(1–40) and (1–42) peptides. Biochemical and Biophysical Research Communications, 
2007. 353(2): p. 443-449. 
16. Iwata, N., M. Higuchi, and T.C. Saido, Metabolism of amyloid-β peptide and 
Alzheimer's disease. Pharmacology & Therapeutics, 2005. 108(2): p. 129-148. 
17. Chong, Y.H. and Y.-H. Suh, Amyloidogenic processing of Alzheimer's amyloid 
precursor protein in vitro and its modulation by metal ions and tacrine. Life Sciences, 
1996. 59(7): p. 545-557. 
18. Pimplikar, S.W., Reassessing the amyloid cascade hypothesis of Alzheimer's disease. 
The International Journal of Biochemistry & Cell Biology, 2009. 41(6): p. 1261-1268. 
62 
 
19. Mann, D.M.A., et al., Saccharides of senile plaques and neurofibrillary tangles in 
Alzheimer's disease. Neuroscience Letters, 1988. 85(2): p. 277-282. 
20. Gong, E.J., et al., Morin attenuates tau hyperphosphorylation by inhibiting GSK3β. 
Neurobiology of Disease, 2011. 44(2): p. 223-230. 
21. Guerreiro, R.J., et al., Genetic screening of Alzheimer's disease genes in Iberian and 
African samples yields novel mutations in presenilins and APP. Neurobiology of 
Aging, 2010. 31(5): p. 725-731. 
22. Masliah, E., R. Terry, and G.r. Buzsa´ki, Thalamic nuclei in Alzheimer disease: 
evidence against the cholinergic hypothesis of plaque formation. Brain Research, 
1989. 493(2): p. 240-246. 
23. Chin, P.C., N. Majdzadeh, and S.R. D'Mello, Inhibition of GSK3β is a common event 
in neuroprotection by different survival factors. Molecular Brain Research, 2005. 
137(1–2): p. 193-201. 
24. Samudralwar, D.L., et al., Elemental imbalances in the olfactory pathway in 
Alzheimer's disease. Journal of the Neurological Sciences, 1995. 130(2): p. 139-145. 
25. Ghosh, A.K., et al., Potent memapsin 2 (β-secretase) inhibitors: Design, synthesis, 
protein-ligand X-ray structure, and in vivo evaluation. Bioorganic & Medicinal 
Chemistry Letters, 2008. 18(3): p. 1031-1036. 
26. Findeis, M.A., The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacology 
& Therapeutics, 2007. 116(2): p. 266-286. 
27. Citron, M., β-Secretase inhibition for the treatment of Alzheimer's disease – promise 
and challenge. Trends in Pharmacological Sciences, 2004. 25(2): p. 92-97. 
28. Ghosh, A.K., et al., Structure-based design, synthesis, and biological evaluation of 
dihydroquinazoline-derived potent β-secretase inhibitors. Bioorganic & Medicinal 
Chemistry Letters, 2012. 22(17): p. 5460-5465. 
63 
 
29. Weiner, M.W., et al., The Alzheimer’s Disease Neuroimaging Initiative: A review of 
papers published since its inception. Alzheimer's & Dementia, 2012. 8(1, 
Supplement): p. S1-S68. 
30. Calabria, M., et al., Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in 
Alzheimer's disease: A 21-month follow-up “real world” study. Archives of 
Gerontology and Geriatrics, 2009. 49(1): p. e6-e11. 
31. Chen, M.J., et al., Gene profiling identifies commonalities in neuronal pathways in 
excitotoxicity: Evidence favouring cell cycle re-activation in concert with oxidative 
stress. Neurochemistry International, 2013. 62(5): p. 719-730. 
32. Reynolds, G.P. and S.L. Kirk, Metabolic side effects of antipsychotic drug treatment – 
pharmacological mechanisms. Pharmacology & Therapeutics, 2010. 125(1): p. 169-
179. 
 
  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
